Infection-related mortality in children with acute lymphoblastic leukemia: An analysis of infectious deaths on UKALL2003

Blood

Volumn 124, Issue 7, 2014, Pages 1056-1061

  O'Connor, David ^a   Bate, Jessica ^b   Wade, Rachel ^c   Clack, Rachel ^c   Dhir, Sunita ^d   Hough, Rachael ^e   Vora, Ajay ^f   Goulden, Nick ^g   Samarasinghe, Sujith ^g  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Newcastle Upon Tyne Hospitals NHS Foundation Trust   (United Kingdom)

^e UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^f SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^g GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; ANTIINFECTIVE AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CHILD; CHILDHOOD LEUKEMIA; CHILDHOOD MORTALITY; DISEASE ASSOCIATION; DOWN SYNDROME; FEMALE; GRAM NEGATIVE INFECTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION; INFECTION RISK; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; TREATMENT RESPONSE; TREND STUDY; UNITED KINGDOM; BACTERIAL INFECTIONS; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; GENETICS; INFANT; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MYCOSES; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; FEMALE; HUMANS; INFANT; MALE; MULTIVARIATE ANALYSIS; MYCOSES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84905993611     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-560847     Document Type: Article

References (31)

1. Pui C-H, Pei D, Sandlund JT, et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):371-382.
2. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012;30(14):1663-1669.
3. Veerman AJ, Kamps WA, van den Berg H, et al Dutch Childhood Oncology Group. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol. 2009;10(10):957-966.
4. van Tilburg CM, Sanders EAM, Nibbelke EE, et al. Impact of reduced chemotherapy treatment for good risk childhood acute lymphoblastic leukaemia on infectious morbidity*. Br J Haematol. 2011;152(4):433-440.
5. Möricke A, Reiter A, Zimmermann M, et al German-Austrian-Swiss ALL-BFM Study Group. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111(9):4477-4489.
6. Christensen MS, Heyman M, Möttönen M, Zeller B, Jonmundsson G, Hasle H; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001. Br J Haematol. 2005;131(1):50-58. (Pubitemid 43899707)
7. Buitenkamp TD, Izraeli S, Zimmermann M, et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014;123(1):70-77.
8. Pui C-H, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730-2741.
9. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-3214.
10. Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14(3):199-209.
11. Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007;110(10):3532-3539. (Pubitemid 350159617)
12. Sung L, Buxton A, Gamis A, Woods WG, Alonzo TA. Life-threatening and fatal infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2012;34(1):e30-e35.
13. Graubner UB, Porzig S, Jorch N, et al. Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50(2):259-263.
14. Ethier MC, Blanco E, Lehrnbecher T, Sung L. Lack of clarity in the definition of treatment-related mortality: pediatric acute leukemia and adult acute promyelocytic leukemia as examples. Blood. 2011;118(19):5080-5083.
15. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16(3):128-140.
16. De Pauw B, Walsh TJ, Donnelly JP, et al. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-1821.
17. National Institute for Health and Care Excellence. Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients. Available at: http://guidance.nice.org.uk/CG151. Accessed: 13 February 2014.
18. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
19. Shah N, Al-Ahmari A, Al-Yamani A, Dupuis L, Stephens D, Hitzler J. Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome. Pediatr Blood Cancer. 2009;52(1):14-19.
20. Rabin KR, Smith J, Kozinetz CA. Myelosuppression and infectious complications in children with Down syndrome and acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012;58(4):633-635.
21. Slats AM, Egeler RM, van der Does-van den Berg A, et al. Causes of death - other than progressive leukemia - in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia. 2005;19(4):537-544. (Pubitemid 40521157)
22. Maloney K, Larsen E, Mattano L, et al. Improved Toxic Mortality Rates for Children with Down Syndrome Acute Lymphoblastic Leukemia (DS-ALL) Treated on Children's Oncology Group (COG) Trials for Standard Risk (SR; AALL0331) but not High Risk (HR; AALL0232) ALL. Pediatr Blood Cancer. 2011;56(6):897-973.
23. Garré ML, Relling MV, Kalwinsky D, et al. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr. 1987;111(4):606-612. (Pubitemid 17140545)
24. Taub JW, Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer. 2005;44(1):33-39. (Pubitemid 39602563)
25. Dare JM, Moppett JP, Shield JP, Hunt LP, Stevens MC. The impact of hyperglycemia on risk of infection and early death during induction therapy for acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2013;60(12):E157-E159.
26. Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol. 2011;164(1):9-16.
27. Patrick K, Wade R, Goulden N, et al. Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol. Br J Haematol. 2014;165(4):552-555.
28. Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study - Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013;31(9):1202-1210.
29. McNeer JL, Nachman JB. The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. Br J Haematol. 2010;149(5):638-652.
30. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO; Medical Research Council Childhood Leukaemia Working Party. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005;129(6):734-745. (Pubitemid 40904523)
31. Belgaumi AF, Al-Bakrah M, Al-Mahr M, et al. Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer. 2003;97(11):2898-2903. (Pubitemid 36605160)